Takara Holdings Inc 2021 Integrated Report
The report describes fiscal 2021 performance during the COVID-19 pandemic, with consolidated net sales of ¥278,443 million and record operating income of ¥21,595 million. It highlights Takara Bio's PCR testing system, molecular epidemiology research and vaccine-development manufacturing cooperation. The report also presents the Takara Group Sustainability Vision, including a consolidated net-zero CO2 target for FY2050.
Company: Takara Holdings Inc
Sector: Manufacturing
Country: Japan
Year: 2021
Type: Integrated Report
Pages: 39
Back to company
Takara Holdings Inc
Takara Group Report
The report describes fiscal 2021 performance during the COVID-19 pandemic, with consolidated net sales of ¥278,443 million and record operating income of ¥21,595 million. It highlights Takara Bio's PCR testing system, molecular epidemiology research and vaccine-development manufacturing cooperation. The report also presents the Takara Group Sustainability Vision, including a consolidated net-zero CO2 target for FY2050.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women in Management
Net Zero Target
Employees